399 related articles for article (PubMed ID: 31359183)
1. Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study.
Ajewole VB; Cox JE; Swan JT; Chikermane SG; Lamoth B; Iso T; Okolo LO; Ford CL; Schneider AM; Hobaugh EC; Baker KR
Support Care Cancer; 2020 Apr; 28(4):1901-1912. PubMed ID: 31359183
[TBL] [Abstract][Full Text] [Related]
2. Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study.
Parsons SK; Rodday AM; Pei Q; Keller FG; Wu Y; Henderson TO; Cella D; Kelly KM; Castellino SM
J Patient Rep Outcomes; 2023 Nov; 7(1):113. PubMed ID: 37947987
[TBL] [Abstract][Full Text] [Related]
3. Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity.
Alberti P; Bernasconi DP; Cornblath DR; Merkies ISJ; Park SB; Velasco R; Bruna J; Psimaras D; Koeppen S; Pace A; Dorsey SG; Argyriou AA; Kalofonos HP; Briani C; Schenone A; Faber CG; Mazzeo A; Grisold W; Valsecchi M; Cavaletti G;
Neurology; 2021 Aug; 97(7):e660-e672. PubMed ID: 34078718
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
5. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
[TBL] [Abstract][Full Text] [Related]
6. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
7. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
Cheng HL; Lopez V; Lam SC; Leung AKT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; De Ng TR; Suen LKP; Chan CW; Yorke J; Molassiotis A
Health Qual Life Outcomes; 2020 Jul; 18(1):246. PubMed ID: 32703223
[TBL] [Abstract][Full Text] [Related]
8. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.
Yeo F; Ng CC; Loh KWJ; Molassiotis A; Cheng HL; Au JSK; Leung KT; Li YC; Wong KH; Suen L; Chan CW; Yorke J; Farrell C; Bandla A; Ang E; Lopez V; Sundar R; Chan A
Support Care Cancer; 2019 Dec; 27(12):4753-4762. PubMed ID: 30972646
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
Bao T; Goloubeva O; Pelser C; Porter N; Primrose J; Hester L; Sadowska M; Lapidus R; Medeiros M; Lao L; Dorsey SG; Badros AZ
Integr Cancer Ther; 2014 Sep; 13(5):396-404. PubMed ID: 24867959
[TBL] [Abstract][Full Text] [Related]
10. Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial.
Bao T; Baser R; Chen C; Weitzman M; Zhang YL; Seluzicki C; Li QS; Piulson L; Zhi WI
Oncologist; 2021 Nov; 26(11):e2070-e2078. PubMed ID: 34390283
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.
Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Mukai H; Katsumata N; Sunada Y; Watanabe T; Hausheer FH
Support Care Cancer; 2009 Dec; 17(12):1483-91. PubMed ID: 19330359
[TBL] [Abstract][Full Text] [Related]
12. Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial.
Lu W; Giobbie-Hurder A; Freedman RA; Shin IH; Lin NU; Partridge AH; Rosenthal DS; Ligibel JA
Oncologist; 2020 Apr; 25(4):310-318. PubMed ID: 32297442
[TBL] [Abstract][Full Text] [Related]
13. Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma.
Han X; Wang L; Shi H; Zheng G; He J; Wu W; Shi J; Wei G; Zheng W; Sun J; Huang H; Cai Z
BMC Cancer; 2017 Jan; 17(1):40. PubMed ID: 28068938
[TBL] [Abstract][Full Text] [Related]
14. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
15. Cryocompression to Reduce Peripheral Neuropathy in Gynecologic Cancer: A Randomized Controlled Trial.
Anastasio MK; Unnithan S; Scott A; Hayes T; Shah S; Moss HA; Erkanli A; Havrilesky LJ
Obstet Gynecol; 2023 Dec; 142(6):1459-1467. PubMed ID: 37883997
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea.
Kim BS; Jin JY; Kwon JH; Woo IS; Ko YH; Park SY; Park HJ; Kang JH
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e448-e454. PubMed ID: 29280313
[TBL] [Abstract][Full Text] [Related]
17. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.
Knoerl R; Weller E; Halpenny B; Berry D
BMC Cancer; 2018 Dec; 18(1):1203. PubMed ID: 30514351
[TBL] [Abstract][Full Text] [Related]
18. Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy.
Hung HW; Liu CY; Chen HF; Chang CC; Chen SC
Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34073174
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer.
Cho K; Saikawa H; Hashimoto T; Katagiri H; Owada Y; Yakuwa K; Fujimura I; Utsumi Y; Akiyama M; Nagashima H; Takahashi F; Maemondo M
Ann Palliat Med; 2023 Nov; 12(6):1136-1145. PubMed ID: 37731302
[TBL] [Abstract][Full Text] [Related]
20. Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538).
Winters-Stone KM; Krasnow SM; Horak FB; Mancini M; Cameron MH; Dieckmann NF; Stoyles SA; Roeland EJ
BMC Cancer; 2023 Nov; 23(1):1087. PubMed ID: 37946117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
